Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date
Lucas Hill,1 Shawn R Smith,1 Maile Young Karris2 1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, USA; 2Department of Medicine, University of California San Diego, San Diego, CA, USA Abstract: Modern pharmacologic management of people living w...
Guardado en:
Autores principales: | Hill L, Smith SR, Karris MY |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3c4c1b585123436693f901fe0c625251 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Potential drug–drug interactions in the era of integrase strand transfer inhibitors: a cross-sectional single-center study in Japan
por: Yusuke Kunimoto, et al.
Publicado: (2021) -
Reversal of Epigenetic Silencing Allows Robust HIV-1 Replication in the Absence of Integrase Function
por: Ishak D. Irwan, et al.
Publicado: (2020) -
Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date
por: Whitfield T, et al.
Publicado: (2016) -
EXPERIENCE WITH DOLUTEGRAVIR IN HIV PATIENTS AT A PUBLIC SECTOR HOSPITAL IN KARACHI, PAKISTAN
por: Farzana Batool, et al.
Publicado: (2021) -
Characterization of the long-terminal repeat single-strand tail-binding site of Moloney-MuLV integrase by crosslinking
por: VERA,JORGE, et al.
Publicado: (2008)